Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Daniel Bradbury of Castle Biosciences sold a total of 13,291 shares of common stock on January 6, 2025, through a pre-arranged 10b5-1 trading plan.
Summary
- Daniel Bradbury, a director at Castle Biosciences, sold 13,291 shares of common stock on January 6, 2025.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
- The transactions were conducted at various prices, with weighted average sale prices of $28.39, $29.41, and $29.82 per share.
- The shares were sold both directly and indirectly through BioBrit, LLC, and irrevocable descendant's trusts.
- Following the transactions, Mr. Bradbury still holds a significant number of shares both directly and indirectly.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for insider stock sales under a pre-arranged plan, which is neither positive nor negative in itself.
Risks
- Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their stock sales while avoiding potential insider trading accusations.
- Many directors and officers at publicly traded companies use similar plans to diversify their holdings or for personal financial planning.
- The reported prices are within the typical range for market transactions, and the volume of shares sold is not unusual for a director's transactions.
Stakeholder Impact
- The stock sale may have a minor impact on the share price, but it is unlikely to be significant given the pre-arranged nature of the transactions.
Key Dates
| Date | Description |
|---|---|
| 05/10/2024 | Date the Rule 10b5-1 plan was adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust. |
| 01/06/2025 | Date of the stock sale transactions. |
| 01/08/2025 | Date the Form 4 was signed. |
Keywords
Form 4, insider trading, stock sale, Rule 10b5-1, Castle Biosciences, Daniel Bradbury, CSTL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.